Unstable mutation of beta-lactamase production in Streptomyces lavendulae.

Antimicrobial Agents and Chemotherapy
M Matsubara-NakanoH Ogawara

Abstract

Streptomyces lavendulae S55-B1 gave two distinct variants at an unusual high frequency: one is a beta-lactamase-nonproducing variant and the other is an Arg- variant. All of the Arg- variants concomitantly had no, or only very low, beta-lactamase activity and were unable to form aerial mycelia or spores. There was no significant linkage between the beta-lactamase activity and the other nutritional requirement which was analyzed. Two of the Arg- variants spontaneously gave Arg+ revertants at a very low frequency. The revertants, however, did not recover the beta-lactamase activity. It is suggested that the beta-lactamase gene may be capable of transposition with inactivation of the arg gene occurring frequently by insertion of the transposed element. Covalently closed circular deoxyribonucleic acid from S55-B1 was not detected by either cesium chloride-ethidium bromide buoyant density centrifugation or agarose gel electrophoresis.

References

Oct 1, 1975·Antimicrobial Agents and Chemotherapy·H Ogawara
Jan 1, 1978·Annual Review of Microbiology·D A Hopwood
Apr 1, 1977·The Journal of Antibiotics·H Ogawara, S Nozaki
May 1, 1976·Journal of General Microbiology·W V Shaw, D A Hopwood
Aug 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·R Benveniste, J Davies
Jan 1, 1974·Molecular & General Genetics : MGG·H SaedlerN Davidson
May 10, 1972·Biochimica Et Biophysica Acta·C Aaij, P Borst

❮ Previous
Next ❯

Citations

Jan 1, 1984·Molecular & General Genetics : MGG·J Altenbuchner, J Cullum
Jan 1, 1985·Molecular & General Genetics : MGG·M HasegawaR Hütter
Jan 1, 1982·Molecular & General Genetics : MGG·S KlausU Taubeneck
Feb 8, 2016·Applied Microbiology and Biotechnology·H Máté de GérandoA M López-Contreras

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.